Polyiclc
Metastatic Hormone Receptor-Positive Breast Carcinoma
Fred Hutchinson Cancer CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Metastatic Hormone Receptor-Positive Breast Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Yb-1 University of Washington | Phase 2 | CCC |
Binimetinib National Cancer Institute (NCI) | Phase 2 | CCC |
c105 University of Washington | Phase 2 | CCC |
cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine University of Washington | Phase 2 | CCC |
FES F-18 University of Washington | Phase 2 | CCC |
SRY-BOX TRANSCRIPTION FACTOR 2 University of Washington | Phase 2 | CCC |
Pidnarulex National Cancer Institute (NCI) | Phase 1 | CC |
Copanlisib National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Polyiclc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →